RNAi Therapeutics Market Size, Share & Growth Trend Analysis Report (2026 - 2035)

Market Outlook

The global RNAi therapeutics market, valued at USD 2.9 billion in 2025, is projected to reach USD 3.6 billion in 2026 and USD 9.1 billion by 2035, representing a CAGR of 10.8% during the forecast period 2026 to 2035.

To learn more about this report, request a free sample copy

Market Report: Key Takeaways

Market Size & Trends

• In terms of type of RNAi molecule, siRNA holds the highest share (65%) of the current market.
• Based on therapeutic area, metabolic disorders capture the largest share of the current market.
• With respect to route of administration, intravenous administration accounts for the highest share, capturing 45% of the current market.
• In terms of key geographical regions, North America currently holds the highest market share.

Key Market Statistics

• Market Size in 2026: USD 3.6 Billion
• Estimated Market Size in 2035: USD 9.1 Billion
• CAGR (2026-2035): 10.8%
• North America: Largest market in 2026
• Asia-Pacific: Fastest-growing region

Market Introduction

RNA interference therapeutics represent a rapidly advancing class of therapies that use small RNA molecules to silence specific genes by neutralizing their corresponding messenger RNA transcripts of disease-associated proteins. By suppressing target mRNA before translation, these therapies reduce the production of disease-associated proteins and enable highly targeted intervention across genetic, metabolic, hematological, ophthalmic, oncological, and other disorders. Since the approval of Onpattro® (patisiran) in 2018, as the first RNAi therapeutic, the modality has evolved from a niche rare disease platform into a clinically validated therapeutic approach with growing commercial relevance.

The RNAi therapeutics market has gained significant momentum due to continued product approvals, expanding therapeutic applications, and advances in drug delivery technologies. For instance, in November 2025, the FDA approved Redemplo® (plozasiran), an apoC-III-directed siRNA therapy developed by Arrowhead Pharmaceuticals, as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome. This approval validates the continued expansion of RNAi therapeutics into metabolic and rare genetic disorders, while reinforcing the clinical and commercial potential of these therapies. Moreover, innovation within the domain is now increasingly focused on extrahepatic and tissue-selective RNAi delivery, with developers exploring platforms designed to reach the central nervous system, eye, tumors, kidney, and other organs. These advances are expected to extend RNAi therapeutics beyond rare and liver-associated diseases into broader therapeutic areas with larger commercial opportunity.

Despite this progress, the RNAi therapeutics industry continues to face challenges related to off-target effects, immune stimulation, extrahepatic delivery, manufacturing complexity, and high treatment costs. Nevertheless, the growing number of approved RNAi products, expanding clinical pipelines, and continued innovation in targeted delivery technologies are expected to create significant opportunities for stakeholders operating in the RNAi therapeutics domain.

Key RNAi Therapeutics

Abbreviations: YoE: Year of Establishment; HQ: Headquarters

Market Segmentation

Based on the research, we have segmented the RNAi Therapeutics Market into type of RNAi molecule, therapeutic area, route of administration, and key geographical regions.

By Type of RNAi Molecule

• siRNA
• shRNA

By Therapeutic Area

• Oncological Disorders
• Genetic Disorders
• Metabolic Disorders
• Hematological Disorders
• Ophthalmic Disorders
• Other Disorders

By Route of Administration

• Subcutaneous
• Intravenous
• Topical
• Intradermal

By Key Geographical Regions

• North America
• Europe
• Asia-Pacific
• Rest of the World

RNAi Therapeutics Market Key Insights

What are the Key Drivers for RNAi Therapeutics Market Growth?

• Increasing Number of FDA Approvals: Continued regulatory approvals are strengthening clinical confidence in RNAi therapeutics and expanding the modality across multiple disease areas. Recent approvals, including Amvuttra® (for ATTR amyloidosis with cardiomyopathy), Qfitlia® (for hemophilia A or B), and Redemplo® (for familial chylomicronemia syndrome), demonstrate the growing therapeutic relevance of RNAi-based medicines beyond the initial rare diseases focus. These approvals are expected to support broader physician adoption, patient access, and commercial expansion of RNAi therapeutics.
• Advances in RNA Chemistry and Targeted Delivery Technologies: Continued innovation in RNA design and targeted delivery is improving the stability, potency, and clinical utility of RNAi therapeutics. Chemical modifications, conjugation strategies, and optimized delivery platforms have enabled more targeted tissue uptake, longer duration of gene silencing, and convenient dosing schedules across several approved and investigational RNAi therapies. These advances are helping developers improve treatment efficacy, reduce dosing burden, and expand the clinical value of RNAi therapeutics.

What are the Main Challenges for RNAi Therapeutics Market Growth?

• Extrahepatic Delivery Limitations: Despite significant progress in liver-targeted delivery, efficient delivery of RNAi to non-hepatic tissues remains a major technical challenge. Several RNAi candidates continue to face barriers related to tissue-specific targeting, cellular uptake, endosomal escape, and sustained gene silencing in non-hepatic tissues. Overcoming these limitations will be critical for expanding RNAi therapeutics into larger disease areas such as oncology, neurology, ophthalmology, and renal disorders.
• Drug Safety, Manufacturing, and Cost Constraints: RNAi therapeutics continue to face challenges related to off-target effects, immune stimulation, chemical modification complexity, manufacturing scalability, and high treatment costs. Developers must carefully optimize RNAi sequences, delivery systems, and dosing regimens to minimize unintended gene silencing, while maintaining therapeutic efficacy. Notably, these requirements can increase development timelines, regulatory scrutiny, and commercialization costs for market participants.

Recent Developments

• In June 2026, Alnylam Pharmaceuticals and Inceptive Nucleics announced a strategic AI-driven collaboration valued at up to USD 2 billion, including USD 30 million upfront, to accelerate RNAi therapeutic discovery. The partnership integrates AI models with RNAi expertise for novel oligonucleotide synthesis, aiming to shorten development timelines and enable advanced oligonucleotide-based drug innovation globally.
• In June 2026, AviadoBio expanded its exclusive license for the vMiX RNAi gene-silencing platform across all human therapeutic areas. The expanded rights extend the AAV-delivered RNAi platform beyond neurology into areas such as cardiovascular disease, nephrology, and oncology, supporting the development of one-time, durable gene-silencing therapies.
• In June 2026, Silence Therapeutics presented follow-up Phase 1 SANRECO data for divesiran at EHA 2026. Divesiran, a first-in-class siRNA targeting TMPRSS6 for polycythemia vera, demonstrated durable reductions in phlebotomy use and improvements in patient-reported outcomes, supporting its continued development in Phase 2 studies.
• In June 2026, City Therapeutics completed a USD 99.5 million Series B financing round to advance its next-generation RNAi engineering platform and pipeline. The proceeds will support the ongoing Phase 1 trial of CITY-FXI for thromboembolic diseases and help advance additional RNAi programs, including CITY-RBP4 for Stargardt disease, toward clinical development.

Industry Experts on RNAi Therapeutics Market

Driven by the clinical validation of approved siRNA therapies and increasing industry focus on programmable gene-silencing platforms, RNAi Therapeutics are moving beyond early rare-disease applications toward broader, high-value therapeutic areas.

Emphasizing this shift, William Soliman (Founder and Chief Executive Officer, Accreditation Council for Medical Affairs), in an interview with Drug Discovery News, stated, "Whoever cracks heart, lung, kidney, CNS delivery with the same precision GalNAc gave the liver will control the next wave of billion-dollar assets."

Discussions with multiple stakeholders in this domain influenced the opinions and insights presented in this study. The market report includes transcripts of the following third-party discussions:

• Founder and Chief Executive Officer, Mid-sized Company, US
• President and Chief Executive Officer, Mid-sized Company, UK
• President and Chief Executive Officer, Small Company, US
• Chief Executive Officer and Co-Founder, Small Company, US
• Chief Executive Officer, Large Company, US
• Senior Vice President, Head of International Region, Large Company, US
• Executive Vice President, Chief Commercial Officer, Large Company, US
• Chief Technology Officer and Head of US Operations, Mid-sized Company, US
• Former Chief Medical Officer, Large Company, US
• Head of Advanced Drug Delivery, Very Large Company, UK

Market Share Insights

Which Type of RNAi Molecule Accounts for the Largest Share in Overall Market?

Based on type of RNAi molecule, the market for RNAi therapeutics is divided into siRNA and shRNA.

According to our market analysis, siRNA occupies the highest market share of 65% in the RNAi therapeutics market. This dominance is primarily driven by the strong clinical validation, regulatory success, and commercial availability of siRNA-based therapies across multiple therapeutic areas. Several approved RNAi products, including Onpattro®, Amvuttra®, Givlaari®, Oxlumo®, Leqvio®, Qfitlia®, and Redemplo®, are based on siRNA technology, reinforcing the segment's leading position. In addition, advances in chemical modification and targeted delivery have improved stability, potency, and dosing convenience of siRNA therapeutics, supporting broader clinical adoption.

In contrast, shRNA is expected to register the highest CAGR during the forecast period. This growth is driven by growing interest in vector-based RNAi approaches that can support longer-duration gene silencing compared to transient RNAi strategies. shRNA platforms are being explored across oncology, genetic disorders, and other difficult-to-address disease areas where sustained suppression of disease-associated genes may offer greater therapeutic value. As developers continue to improve vector design, safety, and tissue-specific expression, shRNA-based approaches are expected to gain significant traction within the RNAi therapeutics industry.

Which Therapeutic Area leads the RNAi Therapeutics Market?

Based on therapeutic area, the RNAi therapeutics market is divided into oncological disorders, genetic disorders, metabolic disorders, hematological disorders, ophthalmic disorders, and other disorders.

Based on the global RNAi therapeutics market forecast and opportunity analysis, revenues generated through the drugs targeting gene silencing in metabolic disorders account for the largest share of the current market. This dominance is primarily driven by the strong commercial adoption of RNAi therapies targeting lipid metabolism and cardiometabolic risk factors. Leqvio®, an siRNA therapy used to reduce LDL cholesterol, generated USD 1.2 billion sales in 2025, achieving blockbuster status and highlighting the commercial strength of RNAi therapies in treatment and management of metabolic indications. Further, the recent approval of Redemplo® (November 2025) for familial chylomicronemia syndrome further supports the growing role of RNAi therapeutics in rare metabolic disorders.

In contrast, revenues generated through the drugs targeting gene silencing in oncological disorders are expected to register the highest CAGR during the forecast period. This growth is driven by the increasing exploration of RNAi approaches for cancer-associated genes that remain difficult to address with conventional treatment strategies. RNAi platforms are being evaluated for their ability to silence oncogenes, resistance pathways, and tumor-promoting molecular targets. As drug delivery technologies improve and developers continue to investigate RNAi-based approaches in combination with existing cancer therapeutics, oncological disorders are expected to emerge as a high-growth therapeutic area within the RNAi therapeutics domain.

Which Route of Administration is Leading the Delivery of RNAi Therapeutics?

Based on routes of administration, the RNAi therapeutics market is segmented into subcutaneous, intravenous, topical, and intradermal routes.

According to our market analysis, intravenous route of administration holds the highest share of 45% in the RNAi therapeutics market. This dominance is primarily driven by the suitability of intravenous route for delivering complex RNAi formulations under medical supervision, particularly in diseases that require structured monitoring, controlled dosing, and treatment through established infusion-center networks. This route gained early clinical and commercial validation with the approval of Onpattro®, the first FDA-approved RNAi therapeutic, which is administered through intravenous infusion. In addition, the higher clinical familiarity and established reimbursement pathways associated with infusion-based therapies have helped intravenous route establish a leading position in the market.

In contrast, subcutaneous route is expected to register the highest CAGR through 2035. This growth is driven by the increasing shift toward convenient, less resource-intensive dosing models that can reduce treatment burden for patients and healthcare systems. The commercial adoption of subcutaneously administered RNAi therapies, including Amvuttra®, Qfitlia®, and Redemplo®, highlights the growing importance of this route of administration. As developers continue to prioritize patient convenience, treatment durability, and outpatient administration, subcutaneous delivery is expected to gain stronger market traction.

Regional Analysis: Which Regions are Showing the Fastest Growth in RNAi Therapeutics Market?

North America Market: Leading the Global Market

On the basis of key geographical regions, the global RNAi therapeutics market is distributed across North America, Europe, Asia-Pacific, and Rest of the World. Among these regions, North America holds the highest market share in the global market. This dominance is primarily driven by the region's strong RNAi innovation ecosystem, established specialty-care infrastructure, and concentration of companies advancing RNAi therapeutics across rare genetic, cardiometabolic, hematological, and neurological indications. Further, ongoing investment in RNAi manufacturing technologies is strengthening regional supply capacity. For instance, in December 2025, Alnylam, a US-based RNAi developer, announced a USD 250 million expansion of its Massachusetts siRNA manufacturing facility. Such initiatives support stronger clinical adoption, manufacturing readiness, and commercial scalability, strengthening North America's leadership in the global market.

Asia-Pacific: An Emerging Growth Spot

The RNAi therapeutics market in Asia-Pacific is expected to grow at the highest rate during the forecast period. This growth is supported by increasing regional RNAi innovation, expanding clinical development activity, and stronger participation of Asia-based companies in global RNAi drug development. China is emerging as a key regional hub, with local developers advancing next-generation siRNA platforms across cardiovascular, metabolic, rare disease, CNS, and viral hepatitis indications. For instance, in September 2025, Shanghai-based Argo Biopharma entered into a multi-asset licensing and option agreement with Novartis for cardiovascular siRNA assets. Such collaborations highlight the growing global relevance of regional RNAi platforms and are expected to support faster market growth within the Asia-Pacific region.

Scope of RNAi Therapeutics Market Report

Frequently Asked Questions

Question 1: What are RNAi therapeutics?

Answer: RNAi therapeutics is a novel class of innovative medicine, utilizing the RNA interference (RNAi) property of genes to regulate expression systems naturally, within the cells.

Question 2: How big is the RNAi therapeutics market?

Answer: The RNAi therapeutics market size is estimated to be worth USD 3.6 billion in 2026.

Question 3: What is the projected market growth of the RNAi therapeutics market?

Answer: The global industry for RNAi therapeutics is expected to grow at a CAGR of 10.8% during the forecast period, from 2026 to 2035.

Question 4: Which region holds the highest market share in the RNAi therapeutics industry?

Answer: North America is likely to capture the majority of the market share in the next decade.

Question 5: Who are the leading companies in the RNAi therapeutics market?

Answer: Leading companies in the RNAi therapeutics market include Alnylam Pharmaceuticals, Arbutus Biopharma, Arrowhead Pharmaceuticals, Benitec Biopharma, Novo Nordisk, Novartis, OliX Pharmaceuticals, Silence Therapeutics, and Sirnaomics.